Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
The Future of Factor XI Inhibitors in Atrial Fibrillation Treatment
The phase 3 OCEANIC-AF trial, comparing the novel factor XI inhibitor asundexian with apixaban in atrial fibrillation patients, was halted early due to futility, raising questions about the future of factor XI inhibitors. Despite early promise, asundexian showed inferior stroke prevention compared to apixaban, with a higher risk of ischemic stroke. Experts suggest the trial's outcome may be due to insufficient factor XI inhibition and emphasize the importance of ongoing research and clinical trials to address the unmet need in anticoagulation therapy.
Mesoglycan Evaluated for Hemorrhoidal Disease in CHORMES Trial
• The CHORMES study is a randomized, double-blind, placebo-controlled trial investigating mesoglycan for treating acute hemorrhoidal disease (HD).
• The primary outcome is the change in Hemorrhoidal Disease Symptom Score (HDSS) from baseline to day 40, assessing symptom reduction.
• Secondary outcomes include changes in HRQoL, safety, fecal continence, bleeding, analgesic use, and pain, measured at various time points.
• The trial aims to enroll 50 patients to demonstrate mesoglycan's superiority over placebo in alleviating HD symptoms with a low incidence of adverse events.
Rivaroxaban Shows Kidney Protection Benefits in Atrial Fibrillation Patients with Advanced CKD
• A prospective observational study, XARENO, indicates that rivaroxaban reduces adverse kidney outcomes in atrial fibrillation patients with advanced chronic kidney disease (CKD).
• Rivaroxaban treatment was associated with a significant reduction in the need for chronic kidney replacement therapy compared to VKA treatment in this patient population.
• The study supports a shift towards proactively using DOACs like rivaroxaban in AF patients with advanced CKD to protect against kidney damage, alongside stroke prevention.
• Findings suggest rivaroxaban may offer kidney-specific benefits beyond traditional anticoagulation by potentially reducing vascular inflammation and calcification.
Real-World Analysis of Nirmatrelvir/Ritonavir Drug-Drug Interactions Shows Low Reporting Rate
• A recent analysis of Pfizer's global safety database reveals a low reporting rate (0.005%) of drug-drug interactions (DDIs) associated with nirmatrelvir/ritonavir (NMV/r).
• Simvastatin was the most frequently reported contraindicated drug, while tacrolimus was the most common drug used with caution in NMV/r-related DDI cases.
• The majority (66.8%) of reported DDI cases were nonserious, with common adverse events including altered taste and gastrointestinal issues, aligning with NMV/r's known safety profile.
• The study underscores the importance of careful patient selection and medication management to mitigate DDI risks, supporting the safe use of NMV/r in treating COVID-19.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath